We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 16, 2019

Trilaciclib Plus Chemotherapy vs Chemotherapy Alone in Patients With Metastatic Triple-Negative Breast Cancer

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Trilaciclib Plus Chemotherapy Versus Chemotherapy Alone in Patients With Metastatic Triple-Negative Breast Cancer: A Multicentre, Randomised, Open-Label, Phase 2 Trial
Lancet Oncol 2019 Sep 27;[EPub Ahead of Print], AR Tan, GS Wright, AR Thummala, MA Danso, L Popovic, TJ Pluard, HS Han, Ž Vojnović, N Vasev, L Ma, DA Richards, ST Wilks, D Milenković, Z Yang, JM Antal, SR Morris, J O'Shaughnessy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading